Loading…
← CockpitCompetitor Analysis › IRON Disc Medicine, Inc.Open in the cockpit ↗

Disc Medicine, Inc.IRONCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops therapies for hematologic diseases involving abnormal red blood cell production and iron metabolism.

Momentum strong 69
Mkt cap
$3.55B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$84.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$77.98
1D+1.8%
1W-10.4%
1M-1.9%
3M-1.1%
6M+16.3%
YTD-1.8%
1Y-13.0%
ATR %5.2%
Beta0.99
52w lowhigh21.6% off high

What Disc Medicine does

Develops therapies for hematologic diseases involving abnormal red blood cell production and iron metabolism.

Develops drugs in-licensed rather than discovered in-house: bitopertin comes from Roche, which dropped it for a different disease. Money to run trials comes from investors until an approved product sells. Rare-disease drugs treat few patients, so they usually carry high prices.

Products and services

  • Bitopertin (erythropoietic porphyrias)
  • DISC-0974 (anemia of myelofibrosis)

Customers

  • Hematologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Hematology: iron and heme metabolism…

What could go right

  • Pivotal trial data readouts
  • Rare disease markets with limited competition

What could go wrong

  • Clinical trial failure risk
  • Small addressable rare-disease markets

Moat: none (IP / patents). Clinical-stage biotech targeting underserved rare hematologic diseases, with no approved products yet.

Headquarters: Watertown, Massachusetts, US · Founded: 2019 · Employees: 155

Named competitors

Disc Medicine at a glance

Size Disc Medicine (IRON) is a United States Health Care company (Biotechnology) with a market value of $3.55B, the 1414th largest of 3,085 United States companies the cockpit tracks. Shares closed at $77.98 on 18 Nov 2026.

Performance Over six months the shares gained 16.3%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.

Short interest Short interest is 17.9% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026IRON 116Peer median 98
Six months, rebased to 100: Disc Medicine against the median of its 20 peers (local-currency closes).

Disc Medicine financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$358,000-$281,000-$156,000-$100,000-$300,000
EBITDA-$265M-$236M-$130M-$91.0M-$47.2M
Net income-$243M-$212M-$109M-$76.4M-$46.8M
Free cash flow-$190M-$181M-$94.4M-$73.6M-$42.4M
Capital expenditure$20,000$933,000$505,000$89,000$151,000
Total debt$61.1M$31.0M$30.0M$2.10M$1.33M

Quarterly statements and history in the cockpit →

Disc Medicine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%ABCL600161IOVARLAY603127TNGX6919ELVNCRSP002007VIRP6696XERSADMA603392TLXDNLIRUBICONIRON6-month return →1-month return →
Up and to the right = strong over both horizons. Disc Medicine is the large dot.

Disc Medicine competitors and peer comparison

Head to head with its named competitors (IRON vs ALNY vs AGIO vs RIGL)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Disc Medicine IRON$3.55B+16%n/an/an/an/a
Alnylam Pharmaceuticals ALNY$20.0B-50%+56%20%3.9×0.5%
Agios Pharmaceuticals AGIO$1.78B+4%+214%-298%8.3×n/a
Rigel Pharmaceuticals RIGL$801M+48%+2%26%2.5×1.5%

How Disc Medicine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Disc Medicine against its 20 peers (data as of 18 Nov 2026)
MeasureIRONPeer medianRank in peer set
1-month return-1.9%-6.1%6th highest of 21
6-month return+16.3%-2.0%8th highest of 21
Distance from 52-week high-21.6%-32.6%5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%11.8×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a

Questions

Who are Disc Medicine's main competitors?
Named competitors: Alnylam Pharmaceuticals (ALNY), Agios Pharmaceuticals (AGIO), Rigel Pharmaceuticals (RIGL). The cockpit's measured peer set (industry) also includes AbCellera Biologics (ABCL), Beijing Tiantan Biological Products (600161.SS), Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY), Joinn Laboratories (China) (603127.SS), Tango Therapeutics (TNGX).
How has Disc Medicine stock performed?
Over six months to 18 Nov 2026 the shares returned +16.3% against -2.0% for the median peer; over one year -13.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.